Advanced Portfolio Management LLC Buys New Stake in Edwards Lifesciences Co. (NYSE:EW)

Advanced Portfolio Management LLC acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,532 shares of the medical research company's stock, valued at approximately $328,000.

A number of other institutional investors also recently bought and sold shares of EW. Norges Bank bought a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $610,895,000. Jennison Associates LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $555,939,000. Vanguard Group Inc. grew its stake in shares of Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock valued at $5,117,845,000 after acquiring an additional 6,537,494 shares during the period. Assenagon Asset Management S.A. raised its stake in Edwards Lifesciences by 475.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company's stock worth $314,182,000 after acquiring an additional 3,506,886 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $213,844,000. Institutional investors own 79.46% of the company's stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 400 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the sale, the vice president now owns 22,588 shares in the company, valued at $1,569,414.24. This represents a 1.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the transaction, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 77,833 shares of company stock worth $5,611,023 over the last three months. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Trading Down 0.2 %

EW stock traded down $0.17 during mid-day trading on Tuesday, reaching $74.94. The company had a trading volume of 2,378,625 shares, compared to its average volume of 5,019,167. The firm has a 50 day moving average of $71.23 and a 200 day moving average of $71.39. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a market capitalization of $44.05 billion, a PE ratio of 10.75, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same period last year, the business posted $0.66 EPS. Edwards Lifesciences's quarterly revenue was up 6.2% on a year-over-year basis. On average, equities analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the topic of several recent analyst reports. Canaccord Genuity Group raised their price objective on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a research report on Friday, April 25th. Evercore ISI cut their target price on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Piper Sandler raised Edwards Lifesciences from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $73.00 to $80.00 in a report on Thursday, April 24th. Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. Finally, Truist Financial lowered their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of "Hold" and a consensus price target of $79.45.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.